BioStem Technologies
BioStem Technologies (OTC: BSEM) is a Florida-based regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products (VENDAJE, Neox, Clarix lines) for advanced wound care, selling to physicians, hospitals, and ambulatory surgery centers via direct sales and distribution partners.
- Company typePublic
- Founded2014
- HeadquartersPompano Beach, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioStem Technologies does
BioStem Technologies, Inc. (OTC: BSEM) is a publicly traded regenerative medicine company founded in 2014 and headquartered in Pompano Beach/Fort Lauderdale, Florida, that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. Its product portfolio includes the VENDAJE family (VENDAJE, VENDAJE AC, VENDAJE OPTIC), the American Amnion sub-brand, and — following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business — the Neox and Clarix cryopreserved amniotic membrane allograft lines. Core technology is the proprietary BioREtain six-step processing method (disinfection, hematopoietic reduction, cold isotonic cleansing, gentle dehydration, precise cutting die placement, and low-dose e-beam terminal sterilization), protected by a portfolio of over 70 patents and manufactured in an AATB-accredited, FDA-registered, cGMP-compliant facility with ISO 5 and ISO 7 suites. BioStem sells direct to wound care physicians, podiatrists, and surgeons and distributes through partners including Venture Medical and the BioTissue-integrated hospital sales force, targeting diabetic foot ulcers, venous leg ulcers, chronic wounds, burns, ocular surface repair, and post-surgical applications under established Medicare HCPCS reimbursement.
The company generates revenue primarily through one-time product sales of allografts and transaction-fee distribution arrangements, with quote-based pricing tied to CMS reimbursement codes such as Q4252 for VENDAJE. Customer segments include wound care specialists, hospital systems, ambulatory surgery centers, and chronic wound patients including VA-adjacent populations. BioStem also operates a wholly owned CDMO subsidiary (BioStem Life Sciences) that offers formulation, regulatory, and supply chain services for biologics, HCT/Ps, and cell and gene therapies, providing optional third-party revenue. Recent strategic priorities include a planned Nasdaq uplisting (Form 10 filed; KPMG engaged as auditor), corporate governance upgrades (Jodi Ungrodt as Audit Committee Chair, Katherine Gorrell as Chief Legal & Compliance Officer), and geographic expansion via future headquarters at Florida Atlantic University's Research Park supporting up to 100 new jobs over five years.
BioStem Technologies firmographics
Firmographics- Name
- BioStem Technologies
- Legal name
- BioStem Technologies, Inc.
- Website
- https://biostemtechnologies.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioStem Technologies (OTC: BSEM) is a Florida-based regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products (VENDAJE, Neox, Clarix lines) for advanced wound care, selling to physicians, hospitals, and ambulatory surgery centers via direct sales and distribution partners.
- Ownership category
- akta.pro rank
BioStem Technologies industry classification
Industry- Product category
- Regenerative Medicine / Wound Care Allografts
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF)
- akta.pro secondary industries
- Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ), Dermatology & Allergy Drugs (HLAMAEAH)
Keywords
Where BioStem Technologies is headquartered
LocationHeadquarters
- HQ city
- Pompano Beach
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BioStem Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Product Sales: BioStem generates revenue from the sale of perinatal tissue allograft products including VENDAJE, VENDAJE AC, VENDAJE OPTIC, American Amnion, Neox, and Clarix product lines. Products are sold to healthcare providers, hospitals, wound care centers, and through distribution partners.
- Distribution Fees: Revenue generated through distribution partnerships such as Venture Medical, where BioStem products are marketed and sold through the partner's network.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
BioStem Technologies product offering
Product offeringCore offering
BioStem Technologies develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care, surgical, and ocular surface applications. Its core offerings include dehydrated human amniotic membrane (VENDAJE) and dehydrated human amniotic/chorionic membrane (VENDAJE AC, American Amnion AC) allografts, an ultra-thin ocular allograft (VENDAJE OPTIC), and cryopreserved amniotic membrane allografts (Neox, Clarix), all produced using the proprietary BioREtain processing method at its cGMP, AATB-accredited, FDA-registered facility.
Product overview
BioStem Technologies is a regenerative medicine company that develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care. The company's product portfolio includes the VENDAJE product line (VENDAJE, VENDAJE AC, VENDAJE OPTIC) and American Amnion sub-brand products, all processed using the proprietary BioREtain method that preserves endogenous biological properties of the tissue. Following the January 2026 acquisition of BioTissue Holdings' surgical and wound care business, the portfolio was expanded to include Neox and Clarix cryopreserved amniotic membrane allografts, extending commercial reach into hospital and surgical settings.
Differentiator
Problem solved
Functional benefit
Brands
- VENDAJE: Dehydrated human amniotic membrane (DHAM) allograft for protective covering of soft tissue wounds
- VENDAJE AC
- VENDAJE OPTIC
- American Amnion
- Neox
- Clarix
- BioStem Life Sciences
Products and services
- VENDAJE VENDAJE is a dehydrated human amniotic membrane (DHAM) allograft composed of the amnion layer of the placental membrane, intended as a protective covering for soft tissue wounds. It is sterilized via e-beam irradiation and stored at ambient temperature with a 4-year shelf life, designed for wound care specialists treating diabetic foot ulcers, venous leg ulcers, and other chronic or acute wounds.
- VENDAJE AC VENDAJE AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft composed of both amnion and chorion layers of the placental membrane, intended as a protective covering for soft tissue wounds. The thicker multi-layer construction provides enhanced tissue protection for complex wounds and burns. HCPCS Q4252 code and Medicare reimbursement established across all MAC regions.
- VENDAJE OPTIC VENDAJE OPTIC is an ultra-thin, dehydrated human amniotic membrane (DHAM) allograft intended for homologous use as a protective covering during the repair of ocular surfaces. It can be applied directly to the eye without additional hardware or sutures, targeting ophthalmic surgeons and ocular surface repair procedures.
- American Amnion American Amnion is a dehydrated human amniotic membrane (DHAM) allograft manufactured using the proprietary BioRetain process, intended as a covering for homologous use in wound care applications. BioStem's sub-brand offering for wound care clinicians treating soft tissue wounds.
- American Amnion AC American Amnion AC is a dehydrated human amniotic/chorionic membrane (DHACM) allograft manufactured using the proprietary BioRetain process, providing enhanced thickness and tensile strength for more robust wound covering applications. Sub-brand offering in the American Amnion line for advanced wound care.
- Neox Neox is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Designed for acute wound care and surgical applications in hospital inpatient, outpatient, and ambulatory surgery center settings.
- Clarix Clarix is a cryopreserved amniotic membrane allograft product acquired from BioTissue Holdings and integrated into BioStem's wound care and surgical portfolio following the January 2026 acquisition. Used in surgical and acute wound care applications in hospital and ambulatory surgery center settings.
Quantifiable outcome
- Nearly 2X probability of wound closure with BioRetain-processed allografts vs standard care in diabetic foot ulcers
- +5 more outcomes
Companies that use BioStem Technologies
Customer profileSegments3 records
Ideal customer profiles2 records
BioStem Technologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioStem Technologies partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- BioTissue Holdings, Inc.coreBioStem acquired BioTissue Holdings' non-ocular surgical and wound care business for up to $40 million, including $15 million upfront cash payment, $10 million potential FDA milestones, and $15 million commercial milestones. Acquisition includes Neox and Clarix cryopreserved amniotic membrane allograft product lines and BioTissue's surgical sales team. BioTissue continues manufacturing these products for BioStem.
- BioTissue Holdings, Inc.corePost-acquisition manufacturing agreement where BioTissue continues to manufacture Neox and Clarix products for BioStem, ensuring supply chain continuity while BioStem integrates the commercial organization.
- Venture MedicalcoreDistribution partnership for nationwide launch of Vendaje AC following established reimbursement in all Medicare Administrative Contractor regions. Venture Medical provides sales and marketing support for physician office market.
- Research institutions for clinical trialssupportingCollaboration with clinical partners for randomized controlled trials on diabetic foot ulcers using Bayesian statistical methodologies, demonstrating superior outcomes with BioRetain-processed allografts.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
BioStem Technologies competitors and assessment
Company assessmentDirect peers
- MiMedx Group: MiMedx is the largest pure-play competitor in dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications, directly competing with BioStem's VENDAJE and American Amnion lines on the same indications, reimbursement codes, and physician-office channel.
- Vivex Biomedical: Vivex Biomedical is a regenerative biologics company developing birth-tissue allograft products (including amniotic membrane grafts) for wound care and orthopedic applications, directly competing with BioStem's VENDAJE line; Dr. Wendy Weston, BioStem's VP of R&D, previously worked at Vivex.
- Organogenesis Holdings: Organogenesis is a regenerative medicine company selling Apligraf and Dermagraft living-cell skin substitutes and PuraPly amniotic products for chronic wound care, directly competing with BioStem's allograft portfolio in DFU/VLU and surgical wound applications.
- Skye Biologics: Skye Biologics develops and commercializes human amniotic membrane and placental tissue allograft products (e.g., Affinity) for wound care and surgical applications, directly competing with BioStem on the same indications and reimbursement framework.
Broad incumbents
- Coloplast: Coloplast operates a Wound & Skin Care business that markets skin-substitute and advanced wound care products to hospitals and home health providers, overlapping with BioStem's VENDAJE/Neox lines on the same DFU/VLU indications.
- Smith+Nephew: Smith+Nephew is a global medical device incumbent with a sizable Advanced Wound Management division (including skin substitute and biological dressing products) that competes with BioStem on hospital wound care contracts and DFU/VLU treatment pathways.
- ConvaTec: ConvaTec's Advanced Wound Care division sells skin substitutes, antimicrobial dressings, and tissue-based products targeting the same DFU/VLU and chronic wound indications as BioStem's allograft portfolio across hospital and home-care channels.
- Integra LifeSciences: Integra LifeSciences is a diversified medical device incumbent with a regenerative tissue technologies and wound care portfolio (AmnioExcel, BioDFence) that overlaps with BioStem's allograft offerings as part of a broader neurosurgery, ENT, and reconstructive surgery franchise.
Emerging players
- Sentry Biologics: Sentry Biologics is an emerging regenerative medicine company marketing cryopreserved and dehydrated amniotic tissue allograft products for chronic and acute wound care, overlapping with BioStem's product portfolio on the same physician-office and hospital channels.
- Vericel Corporation: Vericel is a regenerative medicine company selling autologous and allogeneic cell-based therapies (MACI, Epicel) for cartilage repair and burns, with partial overlap to BioStem's wound-care tissue franchise in burn and complex-wound surgical applications.
Market position
Strengths5 records
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioStem Technologies social profiles
Digital presenceBioStem Technologies compliance and trust
Trust signalCompliance4 records
BioStem Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioStem Technologies leadership team
Management profileNumber of profiles
Profiles14 records
BioStem Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioStem Technologies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioStem Technologies M&A and investment
M&A and investmentM&A5 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioStem Technologies
What does BioStem Technologies do?
BioStem Technologies develops, manufactures, and commercializes perinatal tissue-derived allograft products for advanced wound care, surgical, and ocular surface applications. Its core offerings include dehydrated human amniotic membrane (VENDAJE) and dehydrated human amniotic/chorionic membrane (VENDAJE AC, American Amnion AC) allografts, an ultra-thin ocular allograft (VENDAJE OPTIC), and cryopreserved amniotic membrane allografts (Neox, Clarix), all produced using the proprietary BioREtain processing method at its cGMP, AATB-accredited, FDA-registered facility.
Is BioStem Technologies a public or private company?
BioStem Technologies is a public company. It is classified as public and is currently operating.
When was BioStem Technologies founded?
BioStem Technologies was founded in 2014. It employs 51 to 100 people.
Where is BioStem Technologies based?
BioStem Technologies is headquartered in Pompano Beach, United States, in the North America region.
How does BioStem Technologies make money?
Two revenue lines are on record. Product Sales are the primary driver. The others are distribution Fees.
Who are BioStem Technologies's main competitors?
Direct peers on record are MiMedx Group, Vivex Biomedical, Organogenesis Holdings and Skye Biologics. Broad incumbents are Coloplast, Smith+Nephew, ConvaTec and Integra LifeSciences. Emerging players are Sentry Biologics and Vericel Corporation.
Does BioStem Technologies have an API?
No public API is recorded for BioStem Technologies.
What industry is BioStem Technologies in?
BioStem Technologies's product category is Regenerative Medicine / Wound Care Allografts. Its primary akta.pro industry code is HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services, with a secondary code of HLAAAKAJ, Packaging, Labeling & Serialization Services (biologics/cold chain). Its NAICS code is 325414 and its SIC code is 2836.